Lazard Asset Management
SWTX

Lazard Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Lazard Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,579
Closed -$69K – 2529
2025
Q1 		$69K Buy
1,579
+1,460
+1,227% +$67.2K ﹤0.01% 1921
2024
Q4 		$4K Sell
119
-2,037
-94% -$71.2K ﹤0.01% 2151
2024
Q3 		$69K Sell
2,156
-253
-11% -$9.45K ﹤0.01% 1864
2024
Q2 		$90K Buy
+2,409
New +$101K ﹤0.01% 1781
2021
Q2 		– Sell
-695
Closed -$51K – 2069
2021
Q1 		$51K Buy
+695
New +$54.4K ﹤0.01% 1430

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Lazard Asset Management's SWTX Position: Q2 2025 in Review

Lazard Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 1,579 shares — an estimated $69K sold.

Lazard Asset Management first reported a position in SWTX in Q1 2021 and held it in 5 quarters. The position peaked at $90K in Q2 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Lazard Asset Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 1,579 SpringWorks Therapeutics shares in Q2 2025, an estimated $69K.
  • Lazard Asset Management first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 5 quarters.
  • Lazard Asset Management's SpringWorks Therapeutics position peaked at $90K in Q2 2024.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.